| Cerebrospinal fluid and plasma biomarkers in Alzheimer disease K Blennow, H Hampel, M Weiner, H Zetterberg Nature Reviews Neurology 6 (3), 131-144, 2010 | 2163 | 2010 |
| Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study O Hansson, H Zetterberg, P Buchhave, E Londos, K Blennow, L Minthon The Lancet Neurology 5 (3), 228-234, 2006 | 2125 | 2006 |
| CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis B Olsson, R Lautner, U Andreasson, A Öhrfelt, E Portelius, M Bjerke, ... The Lancet Neurology 15 (7), 673-684, 2016 | 1958 | 2016 |
| Defeating Alzheimer's disease and other dementias: a priority for European science and society B Winblad, P Amouyel, S Andrieu, C Ballard, C Brayne, H Brodaty, ... The Lancet Neurology 15 (5), 455-532, 2016 | 1807 | 2016 |
| Gut microbiome alterations in Alzheimer’s disease NM Vogt, RL Kerby, KA Dill-McFarland, SJ Harding, AP Merluzzi, ... Scientific reports 7 (1), 13537, 2017 | 1644 | 2017 |
| Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis WJ Jansen, R Ossenkoppele, DL Knol, BM Tijms, P Scheltens, ... Jama 313 (19), 1924-1938, 2015 | 1531 | 2015 |
| Neurofilaments as biomarkers in neurological disorders M Khalil, CE Teunissen, M Otto, F Piehl, MP Sormani, T Gattringer, ... Nature Reviews Neurology 14 (10), 577-589, 2018 | 1528 | 2018 |
| Clearance systems in the brain—implications for Alzheimer disease JM Tarasoff-Conway, RO Carare, RS Osorio, L Glodzik, T Butler, ... Nature reviews neurology 11 (8), 457-470, 2015 | 1485 | 2015 |
| CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment N Mattsson, H Zetterberg, O Hansson, N Andreasen, L Parnetti, ... Jama 302 (4), 385-393, 2009 | 1441 | 2009 |
| Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis G Disanto, C Barro, P Benkert, Y Naegelin, S Schädelin, A Giardiello, ... Annals of neurology 81 (6), 857-870, 2017 | 1001 | 2017 |
| Neurofilament light chain as a biomarker in neurological disorders L Gaetani, K Blennow, P Calabresi, M Di Filippo, L Parnetti, H Zetterberg Journal of Neurology, Neurosurgery & Psychiatry 90 (8), 870-881, 2019 | 871 | 2019 |
| Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts TK Karikari, TA Pascoal, NJ Ashton, S Janelidze, AL Benedet, ... The Lancet Neurology 19 (5), 422-433, 2020 | 867 | 2020 |
| Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia S Janelidze, N Mattsson, S Palmqvist, R Smith, TG Beach, GE Serrano, ... Nature medicine 26 (3), 379-386, 2020 | 850 | 2020 |
| Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial L Lannfelt, K Blennow, H Zetterberg, S Batsman, D Ames, J Harrison, ... The Lancet Neurology 7 (9), 779-786, 2008 | 849 | 2008 |
| Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders S Palmqvist, S Janelidze, YT Quiroz, H Zetterberg, F Lopera, E Stomrud, ... Jama 324 (8), 772-781, 2020 | 831 | 2020 |
| Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease N Mattsson, U Andreasson, H Zetterberg, K Blennow, ... JAMA neurology 74 (5), 557-566, 2017 | 830 | 2017 |
| Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives H Hampel, R Frank, K Broich, SJ Teipel, RG Katz, J Hardy, K Herholz, ... Nature reviews Drug discovery 9 (7), 560-574, 2010 | 810 | 2010 |
| The neuropathology and neurobiology of traumatic brain injury K Blennow, J Hardy, H Zetterberg Neuron 76 (5), 886-899, 2012 | 801 | 2012 |
| Biomarkers for Alzheimer's disease: current status and prospects for the future K Blennow, H Zetterberg Journal of internal medicine 284 (6), 643-663, 2018 | 800 | 2018 |
| Cerebrospinal fluid levels ofβ-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia P Buchhave, L Minthon, H Zetterberg, ÅK Wallin, K Blennow, O Hansson Archives of general psychiatry 69 (1), 98-106, 2012 | 779 | 2012 |
